Teva Pharma is trading at $33.31 (5.9% down) in after-hours trading, pulling back after a sharp two-day rally that followed its Q2 2026 earnings release.
- Investors are re-evaluating a headline EPS miss driven by Emalex acquisition costs and a modest overall revenue decline.
- Despite the price drop, the company's innovative brands segment showed strength, surpassing $1 billion in quarterly sales.
- The downward move reflects widespread profit-taking and a more cautious stance from traders following the recent post-earnings surge.